Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Administration of Secukinumab (AIN457) in Patients With Asthma Not Adequately Controlled With Inhaled Corticosteroids and Long Acting Beta-agonists.
Conditions
Interventions
AIN457 (secukinumab)
Placebo
Locations
9
Germany
Novartis Investigative Site
Mainz, Germany, Germany
Novartis Investigative Site
Wiesbaden, Germany, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Großhansdorf, Germany
Novartis Investigative Site
London, United Kingdom, United Kingdom
Start Date
March 1, 2012
Primary Completion Date
November 1, 2014
Completion Date
November 1, 2014
Last Updated
November 20, 2015
NCT07486401
NCT02327897
NCT07219173
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions